Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.
Identifieur interne : 001265 ( Main/Corpus ); précédent : 001264; suivant : 001266Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.
Auteurs : B. Uehleke ; J. Müller ; R. Stange ; O. Kelber ; J. MelzerSource :
- Phytomedicine : international journal of phytotherapy and phytopharmacology [ 1618-095X ] ; 2013.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Analgesics (therapeutic use), Antirheumatic Agents (therapeutic use), Back Pain (drug therapy), Female (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Osteoarthritis (drug therapy), Pain Measurement (MeSH), Phytotherapy (MeSH), Plant Bark (chemistry), Plant Extracts (therapeutic use), Qualitative Research (MeSH), Salix (chemistry), Severity of Illness Index (MeSH), Surveys and Questionnaires (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Analgesics, Antirheumatic Agents, Plant Extracts.
- chemistry : Plant Bark, Salix.
- drug therapy : Back Pain, Osteoarthritis.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pain Measurement, Phytotherapy, Qualitative Research, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome, Young Adult.
Abstract
STUDY OBJECTIVE
Efficacy and safety of willow bark extract for pain reduction in patients suffering from musculoskeletal disorders (MSD) has been shown in clinical short term trials. Therefore this observational study over 6 months should evaluate patterns of treatments like mono- or combinations therapy, dosage and safety during long-term treatment under pragmatic conditions with the aqueous willow bark extract STW 33-I, (Proaktiv(®); drug-extract-ratio 16-23:1).
PATIENTS AND METHODS
The patients were treated with STW 33-I; comedication with other NSAIDs and opioids was allowed. An extensive case report form including pain questionnaires and patient diary was used for outcome evaluation.
RESULTS
Four hundred and thirty-six patients with rheumatic pain mainly due to osteoarthritis (56.2%) and back pain (59.9%) were included. During the study the mean reductions from baseline value 58.4±22.6-31.8±22.5 after 24 weeks in the pain intensity scale (VAS 0-100mm) were significant even after 3 weeks with a reduction by 26 mm (45.6% of the baseline value) at the end of the study. The relative reductions of the weekly means of the daily patient self-rated scores of the pain (6-point Likert-scales) were between 33% and 44% of the baseline values during the course of the study. We present results of subgroups according their analgetic/antiphlogistic comedication. The distribution and specification of the main adverse events and the ratings of the treatment showed a good tolerability. No relevant drug interactions were reported.
CONCLUSION
These data suggest that STW 33-I can be used as a basic treatment in the long-term therapy of painful musculoskeletal disorders and that it can be combined with NSAIDs and opioids if necessary.
DOI: 10.1016/j.phymed.2013.03.023
PubMed: 23731658
Links to Exploration step
pubmed:23731658Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.</title><author><name sortKey="Uehleke, B" sort="Uehleke, B" uniqKey="Uehleke B" first="B" last="Uehleke">B. Uehleke</name><affiliation><nlm:affiliation>Department of Natural Medicine, Charité University Medicine Berlin, Berlin, Germany. bernhard.uehleke@my-campus-berlin.com</nlm:affiliation></affiliation></author><author><name sortKey="Muller, J" sort="Muller, J" uniqKey="Muller J" first="J" last="Müller">J. Müller</name></author><author><name sortKey="Stange, R" sort="Stange, R" uniqKey="Stange R" first="R" last="Stange">R. Stange</name></author><author><name sortKey="Kelber, O" sort="Kelber, O" uniqKey="Kelber O" first="O" last="Kelber">O. Kelber</name></author><author><name sortKey="Melzer, J" sort="Melzer, J" uniqKey="Melzer J" first="J" last="Melzer">J. Melzer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23731658</idno><idno type="pmid">23731658</idno><idno type="doi">10.1016/j.phymed.2013.03.023</idno><idno type="wicri:Area/Main/Corpus">001265</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001265</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.</title><author><name sortKey="Uehleke, B" sort="Uehleke, B" uniqKey="Uehleke B" first="B" last="Uehleke">B. Uehleke</name><affiliation><nlm:affiliation>Department of Natural Medicine, Charité University Medicine Berlin, Berlin, Germany. bernhard.uehleke@my-campus-berlin.com</nlm:affiliation></affiliation></author><author><name sortKey="Muller, J" sort="Muller, J" uniqKey="Muller J" first="J" last="Müller">J. Müller</name></author><author><name sortKey="Stange, R" sort="Stange, R" uniqKey="Stange R" first="R" last="Stange">R. Stange</name></author><author><name sortKey="Kelber, O" sort="Kelber, O" uniqKey="Kelber O" first="O" last="Kelber">O. Kelber</name></author><author><name sortKey="Melzer, J" sort="Melzer, J" uniqKey="Melzer J" first="J" last="Melzer">J. Melzer</name></author></analytic><series><title level="j">Phytomedicine : international journal of phytotherapy and phytopharmacology</title><idno type="eISSN">1618-095X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Analgesics (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Back Pain (drug therapy)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Osteoarthritis (drug therapy)</term><term>Pain Measurement (MeSH)</term><term>Phytotherapy (MeSH)</term><term>Plant Bark (chemistry)</term><term>Plant Extracts (therapeutic use)</term><term>Qualitative Research (MeSH)</term><term>Salix (chemistry)</term><term>Severity of Illness Index (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics</term><term>Antirheumatic Agents</term><term>Plant Extracts</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Plant Bark</term><term>Salix</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Back Pain</term><term>Osteoarthritis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pain Measurement</term><term>Phytotherapy</term><term>Qualitative Research</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>STUDY OBJECTIVE</b></p><p>Efficacy and safety of willow bark extract for pain reduction in patients suffering from musculoskeletal disorders (MSD) has been shown in clinical short term trials. Therefore this observational study over 6 months should evaluate patterns of treatments like mono- or combinations therapy, dosage and safety during long-term treatment under pragmatic conditions with the aqueous willow bark extract STW 33-I, (Proaktiv(®); drug-extract-ratio 16-23:1).</p></div><div type="abstract" xml:lang="en"><p><b>PATIENTS AND METHODS</b></p><p>The patients were treated with STW 33-I; comedication with other NSAIDs and opioids was allowed. An extensive case report form including pain questionnaires and patient diary was used for outcome evaluation.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Four hundred and thirty-six patients with rheumatic pain mainly due to osteoarthritis (56.2%) and back pain (59.9%) were included. During the study the mean reductions from baseline value 58.4±22.6-31.8±22.5 after 24 weeks in the pain intensity scale (VAS 0-100mm) were significant even after 3 weeks with a reduction by 26 mm (45.6% of the baseline value) at the end of the study. The relative reductions of the weekly means of the daily patient self-rated scores of the pain (6-point Likert-scales) were between 33% and 44% of the baseline values during the course of the study. We present results of subgroups according their analgetic/antiphlogistic comedication. The distribution and specification of the main adverse events and the ratings of the treatment showed a good tolerability. No relevant drug interactions were reported.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These data suggest that STW 33-I can be used as a basic treatment in the long-term therapy of painful musculoskeletal disorders and that it can be combined with NSAIDs and opioids if necessary.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23731658</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.</ArticleTitle><Pagination><MedlinePgn>980-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2013.03.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(13)00132-3</ELocationID><Abstract><AbstractText Label="STUDY OBJECTIVE" NlmCategory="OBJECTIVE">Efficacy and safety of willow bark extract for pain reduction in patients suffering from musculoskeletal disorders (MSD) has been shown in clinical short term trials. Therefore this observational study over 6 months should evaluate patterns of treatments like mono- or combinations therapy, dosage and safety during long-term treatment under pragmatic conditions with the aqueous willow bark extract STW 33-I, (Proaktiv(®); drug-extract-ratio 16-23:1).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The patients were treated with STW 33-I; comedication with other NSAIDs and opioids was allowed. An extensive case report form including pain questionnaires and patient diary was used for outcome evaluation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four hundred and thirty-six patients with rheumatic pain mainly due to osteoarthritis (56.2%) and back pain (59.9%) were included. During the study the mean reductions from baseline value 58.4±22.6-31.8±22.5 after 24 weeks in the pain intensity scale (VAS 0-100mm) were significant even after 3 weeks with a reduction by 26 mm (45.6% of the baseline value) at the end of the study. The relative reductions of the weekly means of the daily patient self-rated scores of the pain (6-point Likert-scales) were between 33% and 44% of the baseline values during the course of the study. We present results of subgroups according their analgetic/antiphlogistic comedication. The distribution and specification of the main adverse events and the ratings of the treatment showed a good tolerability. No relevant drug interactions were reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that STW 33-I can be used as a basic treatment in the long-term therapy of painful musculoskeletal disorders and that it can be combined with NSAIDs and opioids if necessary.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uehleke</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Natural Medicine, Charité University Medicine Berlin, Berlin, Germany. bernhard.uehleke@my-campus-berlin.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stange</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kelber</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Melzer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001416" MajorTopicYN="N">Back Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010003" MajorTopicYN="N">Osteoarthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="Y">Phytotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024301" MajorTopicYN="N">Plant Bark</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032108" MajorTopicYN="N">Salix</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Back pain</Keyword><Keyword MajorTopicYN="N">Long-term-study</Keyword><Keyword MajorTopicYN="N">Osteoarthritis</Keyword><Keyword MajorTopicYN="N">Rheumatic pain</Keyword><Keyword MajorTopicYN="N">Willow bark</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23731658</ArticleId><ArticleId IdType="pii">S0944-7113(13)00132-3</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2013.03.023</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001265 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001265 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:23731658
|texte= Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:23731658" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |